SCHEMBL5808530

SCHEMBL5808530

CCN(CC)C(=O)c1cc(C(=O)O)ccn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
MAPT P10636 3/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
KDM5B Q9UGL1 9/20 0.61
KDM5A P29375 5/20 0.61
KDM5C P41229 5/20 0.61
KDM4A O75164 4/20 0.61
FTO Q9C0B1 4/20 0.61
KDM6B O15054 3/20 0.61
ALKBH5 Q6P6C2 3/20 0.61
KDM4E B2RXH2 3/20 0.61
KDM4C Q9H3R0 2/20 0.61
KDM2A Q9Y2K7 2/20 0.61
KDM3A Q9Y4C1 2/20 0.61
TET3 O43151 1/20 0.61
BBOX1 O75936 1/20 0.61
ASPH Q12797 1/20 0.61
KDM4D Q6B0I6 1/20 0.61
TET2 Q6N021 1/20 0.61
KDM7A Q6ZMT4 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5808527 0.90 ALDH1A1 (0.69) ALDH1A1MAPTL3MBTL1KDM5BKDM5A
SCHEMBL3854386 0.88 KDM5B (0.57) ALDH1A1MAPTL3MBTL1KDM5BKDM5A
SCHEMBL5532735 0.83 KDM5B (0.58) ALDH1A1KDM5BKDM5AKDM5CKDM4A
SCHEMBL17819893 0.81 FTO (0.67) ALDH1A1MAPTKDM5BKDM5AKDM5C
SCHEMBL18864232 0.81 FTO (0.53) ALDH1A1MAPTL3MBTL1KDM5BKDM5A
SCHEMBL6239722 0.81 KDM5B (0.49) ALDH1A1MAPTL3MBTL1KDM5BKDM5A
SCHEMBL5210601 0.80 KDM4E (0.56) ALDH1A1MAPTL3MBTL1KDM5BKDM5A
SCHEMBL12677912 0.80 ALDH1A1 (0.69) ALDH1A1MAPTL3MBTL1HPGD
SCHEMBL5214358 0.80 PPARG (0.55) ALDH1A1MAPTL3MBTL1
SCHEMBL6238397 0.79 ALDH1A1 (0.54) ALDH1A1MAPTL3MBTL1KDM5BKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307477-A1 COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS INCLUDING SANGUISORBA OFFICINALIS EXTRACT AS ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-09-19 US disclosed
WO-2023140664-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS INDUCED BY NON-ALCOHOLIC STEATOHEPATITIS, CONTAINING, AS ACTIVE INGREDIENT, EXPRESSION INHIBITOR OF LIPOCALIN 2 OR RECEPTOR THEREOF 경상국립대학교산학협력단 2023-07-27 WO disclosed
WO-2023063663-A1 COMPOSITION FOR PREVENTING OR TREATING HEPATIC FIBROSIS, COMPRISING BETA-GUANIDINOPROPIONIC ACID 주식회사 휴엔켐 2023-04-20 WO disclosed
US-9895370-B2 Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient PHARMEDIX.CO., LTD (KR) 2018-02-20 US disclosed
US-20170143714-A1 Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2017-05-25 US disclosed
WO-2006109996-A1 COMPOSITION COMPRISING THE EXTRACT FROM MELANDRYUM FIRMUM FOR IMPROVEMENT OF LIVER FUNCTION AND TREATMENT OF LIVER DISEASES GENCROSS CO. (KR) 2006-10-19 WO disclosed